NURTEC® ODT achieved preliminary net product revenue of approximately $136 million for the third quarter of 2021
- Launch to date net product revenue for NURTEC ODT is approximately $336 million with over 1,000,000 prescriptions filled since initial product launch in March 2020
- NURTEC ODT is now the market leader for new oral migraine therapies and currently accounts for approximately 61% of new-to-brand prescriptions (NBRx) for oral CGRP-targeting drugs
https://finance.yahoo.com/news/biohaven-announces-preliminary-3q2021-net-113000769.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.